Search Results - "Romeder, F"

Endothelin-1 genetic polymorphism as predictive marker for bevacizumab in metastatic breast cancer by Gampenrieder, S P, Hufnagl, C, Brechelmacher, S, Huemer, F, Hackl, H, Rinnerthaler, G, Romeder, F, Monzo Fuentes, C, Morre, P, Hauser-Kronberger, C, Mlineritsch, B, Greil, R

“…Biomarkers for bevacizumab efficacy in metastatic breast cancer (MBC) are of urgent need. The genetic variability of genes involved in angiogenesis could…”
Get full text

Multicenter phase II study evaluating docetaxel and cisplatin as neoadjuvant induction regimen prior to surgery or radiochemotherapy with docetaxel, followed by adjuvant docetaxel therapy in chemonaive patients with NSCLC stage II, IIIA and IIIB (TAX-AT 1.203 Trial) by Kocher, F, Pircher, A, Mohn-Staudner, A, Romeder, F, Duller, W, Steinmaurer, M, Eckmayr, J, Schmid, T, Hilbe, W, Fiegl, M, Greil, R

“…Highlights • Response to neoadjuvant induction chemotherapy in locally advanced NSCLC. • 34% of initially unresectable patients became resectable upon…”
Get full text

Abstract P3-07-43: DNA methylation patterns correlating with outcome in patients treated with first-line bevacizumab for metastatic breast cancer by Gampenrieder, SP, Rinnerthaler, G, Weinhäusel, A, Pulverer, W, Hugnagl, C, Hackl, H, Romeder, F, Monzo Fuentes, C, Hauser-Kronberger, C, Mlineritsch, B, Greil, R

“…Background: Biomarkers predicting response to bevacizumab containing therapy in breast cancer are of urgent need for a personalized treatment approach. DNA…”
Get full text

MiR-16 is the most stable-expressed housekeeping microRNA in breast cancer tissues from primary and metastatic sites by Rinnerthaler, G., Hackl, H., Hamacher, F., Gampenrieder, S.P., Hufnagl, C., Romeder, F., Monzo Fuentes, C., Hauser-Kronberger, C., Mlineritsch, B., Greil, R.

Get full text

Abstract P1-08-32: Endothelin-1 genetic polymorphism as predictive marker for bevacizumab in metastatic breast cancer by Gampenrieder, SP, Hufnagl, C, Brechelmacher, S, Huemer, F, Hackl, H, Rinnerthaler, G, Romeder, F, Muß, C, Pircher, M, Ressler, S, Kronberger, C, Mlineritsch, B, Greil, R

“…Background: Biomarkers predicting response or toxicity of bevacizumab containing therapy in breast cancer are of urgent need. The genetic variability of VEGF,…”
Get full text

Oxaliplatin, Irinotecan, Bevacizumab followed by Docetaxel, Bevacizumab in Inoperable Gastric Cancer. A Multicenter Phase II Trial (AGMT Gastric-3) of the Arbeitsgemeinschaft Medikamentöse Tumortherapie (AGMT) by Wöll, E., Keil, F., Thaler, J., Gruenberger, B., Hejna, M., Eisterer, W., Fridrik, M.A., Romeder, F., Greil, R.

Get full text

Abstract P5-20-11: Bevacizumab in metastatic breast cancer: a retrospective matched-pair analysis by Gampenrieder, SP, Romeder, F, Muß, C, Pircher, M, Ressler, S, Rinnerthaler, G, Bartsch, R, Sattlberger, C, Mlineritsch, B, Greil, R

“…Background: In November 2011 the FDA withdrew accelerated approval of the breast cancer indication for bevacizumab, because “the drug has not been shown to be…”
Get full text

Oxaliplatin, irinotecan, and bevacizumab followed by docetaxel and bevacizumab in inoperable gastric cancer: First results of a multicenter phase II trial (AGMT Gastric-3) of the Arbeitsgemeinschaft Medikamentoese Tumortherapie (AGMT) by Woell, E., Keil, F., Thaler, J., Gruenberger, B., Hejna, M., Eisterer, W., Fridrik, M. A., Romeder, F., Greil, R.

“…Abstract only…”
Get full text

Treatment of patients with radioiodine refractory, differentiated thyroid carcinoma. A Consensus Statement by Lindner, Christina, Dierneder, J, Pall, G, Pirich, C, Hoffmann, M, Raderer, M, Becherer, A, Niederle, B, Lipp, R, Lind, P, Gallowitsch, H, Romeder, F, Virgolini, I

“…There is no clear standard therapy for patients with radioactive iodine (131I)-refractory locally advanced or metastatic differentiated thyroid cancer. The…”
Get more information

P252 LONGITUDINAL CHANGE OF ARTICULAR CARTILAGE MORPHOLOGY AS A FUNCTION OF VARUS AND VALGUS MALALIGNMENT IN KNEE OSTEOARTHRITIS by Romeder, F., Eckstein, F., Hudelmaier, M., Marshall, M., Sharma, L.

Get full text